Dr. Agarwal’s Health Care IPO date, Share Price Target Tomorrow, 2025, 2026, 2030

Dr. Agarwal’s Health Care founded in 2010, operates across India and several African countries. It offers various eye care services, including surgeries, consultations, and products. The company has seen strong growth, with most of its revenue from surgeries. With a growing demand for eye care, particularly in India and Africa, It is a well-positioned company for continued growth.

What is Dr. Agarwal’s Health Care IPO?

 Dr. Agarwal’s Health Care was founded in 2010 by Dr. J. Agarwal in Chennai, Tamil Nadu, with a focus on providing high-quality eye care. The first hospital mainly treated eye conditions like cataracts, glaucoma, and refractive issues. Over the years, it expanded to offer a wider range of medical services and now has hospitals in many cities across India and other countries. It is known for its advanced technology, skilled doctors, and patient-focused care, this health care has become a trusted name in the healthcare industry, making healthcare affordable and accessible to many.

Denta Water IPO Detail

IPO Date	January 29, 2025 to January 31, 2025
Listing Date	[.]
Minimum Investment	₹13,370.00
Face Value	₹1 per share
Price Band	₹382 to ₹402 per share
Lot Size	35 Shares
Total Issue Size	7,53,04,970 shares (aggregating up to ₹3,027.26 Cr)
Fresh Issue	74,62,686 shares (aggregating up to ₹ 300.00 Cr)
Offer for Sale	6,78,42,284 shares of ₹1 (aggregating up to ₹2,727.26 Cr)
Issue Type	Book Built Issue IPO
Listing At	BSE, NSE
Share Holding Pre Issue	30,84,17,160 shares
Share Holding Post Issue	31,58,79,846 shares

Dr Agarwal’s Health Care Share Price Target Tomorrow

In FY24. 64.20% of its revenue came from surgeries, 12.83% from optical products, and the rest from eye care medicines. Between FY22 and FY24, its revenue grew by 38.34% annually, and its profit increased by 48.39%. The Indian eye-care market is expected to grow 12-14% annually, and the company’s hub-and-spoke model is expanding to underserved areas, with 123 facilities in Tier-II and Tier-III cities. This shows the company has strong fundamentals with are very important for investment.

Day	Minimum Price (Rs)	Maximum Price (Rs)
Tomorrow	480	350

Dr Agarwal’s Health Care Share Price Target 2025

The company is expected to experience steady growth as it continues expanding its network and enhancing its medical capabilities. The company’s success in treating over 21 lakh patients and performing over 220,000 pulse surgeries in the past year will likely attract investor attention.

With an increasing share of revenue coming from surgical procedures, along with a growing base of satisfied patients, the share price is expected to gradually rise. The company’s focus on high-quality services and its reputation as a trusted name in eye care will play a key role in boosting its market value. So in 2025, Its stock price target would be ₹590 as per our analysis.

By our prediction, its stock price would be between ₹350 to ₹590 in 2025.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	350	590

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	350	480
February	376	393
March	383	410
April	390	427
May	400	440
June	411	449
July	428	473
August	458	490
September	480	520
October	495	539
November	523	556
December	530	590

Dr Agarwal’s Health Care Share Price Target 2026

This company has already made good progress in expanding across India, with more than 193 facilities in 117 cities. The company’s plan to open more Centers of Excellence, which offer advanced surgeries and training programs, will help it grow. As the need for eye care services increases, especially in smaller cities, the company’s efficient way of expanding into new areas will likely boost its share price. In 2026, its stock price target would be ₹767 as per our analysis.

By our prediction, its stock price would be between ₹530 to ₹767 in 2026.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	530	767

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	530	600
February	539	620
March	557	639
April	579	655
May	591	673
June	608	680
July	637	690
August	643	700
September	667	728
October	683	739
November	720	746
December	738	767

Share price Target 2027

The company’s focus on growing both naturally and by acquiring new facilities should lead to stronger financial performance. As the company continues to expand its presence in key areas, it will be able to capture more market share. This growth in infrastructure and reach will likely result in higher revenue and better efficiency, which can drive up the share price. With its trusted brand and leadership from experienced doctors, the company will also remain an attractive option for investors. In 2027, its stock price target would be ₹900 as per our analysis.

By our prediction, its stock price would be between ₹738 to ₹900 in 2027.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	738	900

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	738	780
February	751	800
March	768	810
April	789	820
May	800	838
June	818	845
July	830	861
August	843	870
September	840	865
October	855	878
November	850	883
December	871	900

Share price Target 2028

With the Indian eye care market expected to grow a lot in the next few years, the company is in a great position to take advantage of this growth. Its focus on expanding into emerging markets like Africa, where the demand for healthcare is rising, will help its global expansion. Also, its strong financial performance in recent years will likely increase investor confidence in the company’s future growth. So in 2028, its stock price target would be ₹1089 as per our analysis.

By our analysis, its stock price would be between ₹ 870to ₹1089 in 2028.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	870	1089

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	871	921
February	885	943
March	897	968
April	910	980
May	941	963
June	955	983
July	968	997
August	980	1010
September	997	1024
October	1012	1038
November	1030	1068
December	1056	1089

Share price Target 2029

The company is investing in training, advanced technology, and new surgeries like robotic cataract surgery, which will help improve its reputation for high-quality care. As the demand for eye care in India keeps rising, the company’s growing number of patients and continued expansion will likely lead to steady revenue growth. As the company becomes financially stronger, its share price is expected to increase due to the rising demand for its eye care services. By 2029, its stock price target would be ₹1290 as per our analysis.

As per our prediction, its stock price would be between ₹1056 to ₹1290 in 2029.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	1056	1290

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1056	1100
February	1073	1121
March	1089	1143
April	1097	1167
May	1127	1178
June	1139	1183
July	1158	1198
August	1178	1210
September	1190	1228
October	1218	1236
November	1228	1270
December	1255	1290

Dr Agarwal’s Health Care share price Target 2030

With more hospitals and medical centres opening, especially in growing markets, the company is set for long-term success. By focusing on new surgical treatments and keeping patients satisfied, the company should keep growing in both revenue and share price. As the demand for eye care increases in India and the company expands internationally, it will strengthen its position as a leader in the industry, which will likely boost its stock value. In 2030, its stock price target would be ₹1569 as per our analysis.

By our prediction, its stock price would be between ₹1255 to ₹1569 in 2030.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	1255	1569

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1255	1300
February	1283	1320
March	1298	1331
April	1318	1340
May	1328	1353
June	1340	1370
July	1354	1390
August	1368	1437
September	1383	1480
October	1355	1520
November	1456	1550
December	1520	1569

Share price Target 2040

This company is expected to remain a leader in the global eye care market. The company’s ability to expand into fast-growing areas while continuing to innovate in surgeries will help it stay ahead of competitors. As it grows in underserved areas, both in India and globally, the company’s share price is likely to show its long-term value. Its flexible business model and focus on improving patient care will help it remain an industry leader, making its stock a good long-term investment. So by 2040, its stock price target would be ₹3410 as per our analysis.

By our prediction, its stock price would be between ₹2970 to ₹3410 in 2040.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	2970	3410

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	2970	3020
February	2990	3037
March	3010	3060
April	3037	3088
May	3055	3120
June	3080	3160
July	3125	3210
August	3180	3258
September	3210	3280
October	3239	3334
November	3310	3380
December	3350	3410

Share price Target 2050

It is likely to become a well-known brand around the world, with a strong presence in both developed and growing markets. The company’s plan to expand into areas with less access to eye care and focus on new eye care technology will help it stay ahead of competitors. As it continues to grow and meet the increasing need for eye care, its share price is expected to increase. Investors can expect good returns from this company because of its strong reputation and leadership in the eye care field. In 2050, its stock price target would be ₹5630 as per our analysis.

By our prediction, its stock price would be between ₹4842 to ₹5630 in 2050.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	4842	5630

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	4842	4873
February	4860	4930
March	4884	4963
April	4928	4980
May	4955	5020
June	4980	5039
July	5010	5090
August	5046	5180
September	5150	5278
October	5250	5390
November	5355	5510
December	5450	5630

Should I buy Dr Agarwal’s Health Care stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	350	590
2026	530	767
2027	738	900
2028	870	1089
2029	1056	1290
2030	1255	1569
2040	2970	3410
2050	4842	5630

It has great growth potential with its expanding presence, especially in places like India and Africa where eye care is in high demand. The company is also investing in new technology and surgeries, which will help it grow even more. If you’re interested in a long-term investment in the healthcare sector, this stock might be a good choice. However, make sure to do your research or talk to a financial advisor before deciding.

Dr Agarwal’s Health Care earning results (Financials)

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Sales +	176	140	201	268	319
Expenses +	129	109	143	192	227
Operating Profit	47	31	59	76	92
OPM %	27%	22%	29%	28%	29%
Other Income +	3	1	1	2	5
Interest	9	7	7	8	8
Depreciation	21	19	20	20	27
Profit before tax	20	6	32	49	62
Tax %	31%	125%	25%	25%	26%
Net Profit +	14	-1	24	37	46
EPS in Rs	29.11	-3.06	51.28	78.55	98.64
Dividend Payout %	0%	0%	6%	4%	3

Is Dr. Agarwal’s Health Care stock good to buy? (Bull case & bear case)

Bull Case

• 31.4% profit growth over the last 5 years.
• Impressive 36.1% ROE over 3 years.
• Trusted brand with strong expansion in India and Africa.
•  Investing in advanced surgeries like robotic cataract surgery.

Bear Case

• The stock is trading at 15.4 times its book value, which may be overvalued.
• Possible concern about financial transparency.
• Promoters have pledged 55.4% of their stake, adding financial risk.

Dr Agarwal’s Health Care IPO Promoter Holding

The Promoters of the Company are Dr Amar Agarwal, Dr Athiya Agarwal, Dr Adil Agarwal, Dr Anosh Agarwal, Dr Ashvin Agarwal, Dr Ashar Agarwal, Dr Amar Agarwal Family Trust, Dr Adil Agarwal Family Trust, Dr Anosh Agarwal Family Trust, Dr Ashvin Agarwal Family Trust, Dr Ashar Agarwal Family Trust, Dr Agarwal’s Eye Institute and Dr Agarwal’s Eye Institute Private Limited.

Share Holding Pre Issue	37.72%
Share Holding Post Issue	—

Objects of the Issue (Dr. Agarwal’s Health Care IPO Objectives)

The company plans to use the money raised from the new shares for:

• Paying off some or all of its loans.
• General business purposes and potential future acquisitions that are not yet identified.

Dr Agarwal’s Health Care IPO GMP

Date	IPO GMP	Kostak	Subject to
25 January	₹55	₹-	₹2000
24 January	₹-	₹-	₹-

Conclusion

This has good growth potential with its expansion in India and Africa, plus investments in new technology. However, the stock might be a bit expensive, and there are some concerns about financial transparency and the promoters’ pledged shares. We have details about this stock in this article. It could be a good long-term investment, but it’s important to do your research before buying.

FAQs